Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 outpatient ecopipam study for self-injurious behavior in Lesch-Nyhan disease
2012-002662-12Phase 3Active
- Sponsor
- Emalex Biosciences
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ecopipam in Lesch-Nyhan syndrome (LNS), sponsored by Emalex Biosciences. Primary endpoints: Behavior Problems Inventory self-injurious behavior frequency and Behavior Problems Inventory self-injurious behavior severity. Started Sep 2012; status: active.
02
Drugs
ecopipam
03
Conditions
Lesch-Nyhan syndrome (LNS)
Beyond the preview
Go deeper on 2012-002662-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002662-12.